Fundz

Salarius Pharmaceuticals reported raising $6 Million in an initial SEC Form D filing, from an offering of $6 Million

PUBLIC · DCOYMay 25, 2023

Amount Raised

$6 Million

$6 Million sold, per SEC Form D (first sale May 11, 2023)

Round Type

Venture

HoustonBiotechnologyHealth CareMedicalTherapeuticsPharmaceuticalBiopharma

Quick answer

Decoy Therapeutics Inc. raised $6 Million in a funding round, dated May 11, 2023. Decoy Therapeutics Inc. is based in Houston, Texas, United States.

How much did Decoy Therapeutics Inc. raise?
Decoy Therapeutics Inc. raised $6 Million in a funding round on May 11, 2023.
What does Decoy Therapeutics Inc. do?
Salarius Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing cancer therapies for patients in need of new treatment options.
Where is Decoy Therapeutics Inc. based and how big is it?
Decoy Therapeutics Inc. is based in Houston, Texas, United States.
Who are the decision-makers at Decoy Therapeutics Inc?
Fundz holds 1 contact at Decoy Therapeutics Inc., including the CEO. Names and contact details are shown to Fundz members.

Source: Fundz verified event record.

Who else raised in Medical and Therapeutics around the same time

Companies in the same sectors as Decoy Therapeutics Inc. that raised within 45 days of this round, from Fundz verified event records.

  • Alkeus Pharmaceuticals raised $150M (Series B) on June 5, 2023.
  • Renibus Therapeutics raised $64M on May 25, 2023.
  • Qnovia raised $2.9M on May 25, 2023.
  • Mezzion Pharma raised $40M (Funding Round) on April 25, 2023.
  • Milestone Pharmaceuticals raised $125M on March 28, 2023.
  • DiaMedica Therapeutics raised $38M on June 23, 2023.

Who to call at Decoy Therapeutics Inc., and when

A new round usually means Decoy Therapeutics Inc. is about to hire and buy. The teams that reach out first get the meeting.

  • An alert the day Decoy Therapeutics Inc. raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at Decoy Therapeutics Inc., from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at Decoy Therapeutics Inc.. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

Decoy Therapeutics Inc.

Location

2450 Holcombe Blvd.

Houston, Texas, United States

About

Salarius Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing cancer therapies for patients in need of new treatment options. Salarius’ product portfolio includes seclidemstat, a reversible LSD1 inhibitor, which is being studied as a potential treatment for pediatric cancers, sarcomas, and other cancers with limited treatment options, and SP-3164, an oral small molecule targeted protein degrader. Seclidemstat is currently in a Phase 1/2 clinical trial for relapsed/refractory Ewing sarcoma and select additional sarcomas that share a similar biology to Ewing sarcoma, also referred to as Ewing-related or FET-rearranged sarcomas. Seclidemstat has received Fast Track Designation, Orphan Drug Designation, and Rare Pediatric Disease Designation for Ewing sarcoma from the U.S. Food and Drug Administration. Salarius is also exploring seclidemstat’s potential in several cancers with high unmet medical need, with a second Phase 1/2 clinical study in hematologic cancers, initiated by MD Anderson Cancer Center. Salarius has received financial support from the National Pediatric Cancer Foundation to advance the Ewing sarcoma clinical program and was also a recipient of a Product Development Award from the Cancer Prevention and Research Institute of Texas (CPRIT). For more information, please visit salariuspharma.com or follow Salarius on Twitter and LinkedIn.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment Decoy Therapeutics Inc. raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Related People

1 contact
Verified contactsDavid A., CEOSee plans and pricing
Predictive Intelligence
Strategic

ML-powered predictions for Decoy Therapeutics Inc.'s next move

See what Strategic adds

Decoy Therapeutics Inc. raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.